Getty Images
The benefits of the Johnson & Johnson Janssen coronavirus vaccine still outweigh potential risks
By Jacqueline Howard, CNN
The benefits of the Johnson & Johnson Janssen coronavirus vaccine still outweigh potential risks, according to data from the US Centers for Disease Control and Prevention.
“Many hospitalizations, ICU admissions and deaths can be prevented through Janssen and mRNA Covid-19 vaccines, far outweighing the risks,” CDC researcher Dr. Hannah Rosenblum told the agency’s Advisory Committee on Immunization Practices in a meeting on Thursday. The Pfizer/BioNTech and Moderna vaccines are messenger RNA or mRNA vaccines.
Earlier this month, the US Food and Drug Administration updated the label on Johnson & Johnson’s coronavirus vaccine to warn of the possible increased risk of a rare neurological complication known as Guillain-Barré syndrome (GBS).
Johnson & Johnson coronavirus vaccine s benefits still outweigh risks, US CDC data show
By
Jacqueline Howard, CNN
enablePagination: false
endIndex:
(CNN) The benefits of the Johnson & Johnson Janssen coronavirus vaccine still outweigh potential risks, according to data from the US Centers for Disease Control and Prevention. Many hospitalizations, ICU admissions and deaths can be prevented through Janssen and mRNA Covid-19 vaccines, far outweighing the risks, CDC researcher Dr. Hannah Rosenblum told the agency s Advisory Committee on Immunization Practices in a meeting on Thursday. The Pfizer/BioNTech and Moderna vaccines are messenger RNA or mRNA vaccines.
Earlier this month, the US Food and Drug Administration updated the label on Johnson & Johnson s coronavirus vaccine to warn of the possible increased risk of a rare neurological complication known as Guillain-Barré syndrome (GBS).
What Pfizer s plan for a third coronavirus vaccine dose means for you localnews8.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from localnews8.com Daily Mail and Mail on Sunday newspapers.
Pool/Getty Images
By Jacqueline Howard, CNN
Even though the biopharmaceutical company Pfizer has announced that it might be time to consider giving a third dose of its coronavirus vaccine to people, many doctors and public health officials argue that it’s more beneficial to get shots into the arms of the unvaccinated right now than to boost those who are already fully vaccinated.
“It’s wonderful to have a booster approved for emergency use authorization on the shelf ready to go any time we need it. But I do not think we need it right now,” Dr. William Schaffner, a professor at Vanderbilt University School of Medicine and medical director of the National Foundation for Infectious Diseases, told CNN on Friday.
Getty Images for Empire State Re
Monica Schipper/Getty Images
A healthcare worker administers the vaccine as the Empire State Building offers Covid-19 vaccines at its observatory on June 18
By Jacqueline Howard, CNN
Vaccine makers are preparing for a next possible phase of the Covid-19 vaccine rollout: booster doses.
The biopharmaceutical company Pfizer announced on Thursday that it has seen waning immunity from its coronavirus vaccine although efficacy in preventing serious illness remains high but did not detail the evidence. It said a third dose may be needed six to 12 months after full vaccination.
The company said it would publish “more definitive data soon” and in August would seek emergency use authorization from the US Food and Drug Administration for a booster dose.